Life science commercialization agency CG Life has announced its acquisition of The Considered+AI. This partnership unites CG Life’s deep scientific expertise with the innovative, AI-native operating model of The Considered+AI. The combination aims to create a formidable new agency alternative, specifically designed to challenge larger, traditional networks in the evolving pharmaceutical landscape.
A Union of Complementary Strengths
Under the terms of the deal, The Considered+AI founder David Hunt will continue as CEO of the agency while also joining CG Life’s board. This arrangement ensures leadership continuity and integrates his entrepreneurial vision into the broader organization. The merger is positioned as a blend of CG Life's established scientific commercialization prowess with The Considered+AI's modern, tech-forward approach.
Founded in 2003, CG Life has built a strong reputation for commercializing treatments for rare and hard-to-treat diseases. The private equity-backed firm recently expanded its client base to 45, boosting its revenue to $35 million. Its comprehensive services include strategy, public relations, and omnichannel engagement, providing a solid foundation for the new partnership.
The Considered+AI, established in 2021, has experienced remarkable growth as a remote-first, AI-native agency. Its revenue surged to $21.1 million with a client roster that includes industry leaders like Novartis, Otsuka, and Sanofi. The agency's success was recently recognized when it was named Small Healthcare Agency of the Year at the 2025 MM+M Awards.
Challenging the Traditional Agency Model
The acquisition is driven by a shared entrepreneurial spirit between CG Life CEO David Ormesher and David Hunt. Both leaders emphasize their focus on building what does not yet exist, rather than simply managing established structures. This shared DNA forms the core of their strategy to offer a distinct alternative in the agency marketplace.
Ormesher noted that legacy agency models are not built for the current environment, which is defined by AI, post-pandemic work styles, and a new generation of brand managers. The combined entity aims to be more nimble and responsive to pharmaceutical clients who are working with leaner internal teams. This agility is presented as a key competitive advantage against larger, more bureaucratic holding companies.
Harnessing AI for Enhanced Effectiveness
A central element of this merger is the integration of The Considered+AI’s advanced approach to artificial intelligence. David Hunt clarified that the goal is not merely to increase speed or cut costs. Instead, the focus is on leveraging AI to become exponentially more effective and to augment the strategic capabilities of their talented teams.
CG Life plans to learn from and adopt the AI-native culture that has powered its new partner's success. This involves fostering a workplace where employees are encouraged to experiment with AI tools and share best practices across the organization. The synergy will combine this innovative culture with CG Life’s existing strengths in technology, PR, and corporate communications.
Ultimately, this acquisition represents more than a simple business combination; it is a deliberate effort to construct a new type of agency. By merging deep scientific knowledge with an AI-centric culture, CG Life and The Considered+AI are betting on a new model of scale measured by impact, not headcount. Their stated goal is to build an agency prepared for the next generation of therapies and marketers.